세계의 전이성 거세저항성 전립선암(mCRPC) 치료제 시장 : 규모, 점유율, 성장 및 산업 분석, 유형별, 용도별, 지역별 인사이트 및 예측(2024-2032년)

Growth Factors of metastatic castration-resistant prostate cancer (mCRPC) therapeutics Market

The global metastatic castration-resistant prostate cancer (mCRPC) therapeutics market is undergoing significant expansion as the prevalence of advanced prostate cancer rises and pharmaceutical companies accelerate innovation in targeted and hormonal therapies. According to the 2024 assessment, the market size reached USD 16.46 billion in 2024, underscoring the growing patient pool requiring advanced treatments after resistance to standard hormone therapy. The market is projected to increase sharply to USD 21.04 billion in 2025 and further surge to USD 87.19 billion by 2032, exhibiting a robust CAGR of 22.5% during 2025-2032.

With 53.77% share in 2024, North America remained the dominant regional market, supported by advanced oncology care systems, strong reimbursement policies, and rapid introduction of next-generation therapies.

Rising Global Burden of Aggressive Prostate Cancer

mCRPC represents the most advanced and life-threatening form of prostate cancer, characterized by metastasis to organs such as the bones, liver, and lymph nodes, along with resistance to androgen deprivation therapy (ADT). The escalating prevalence of prostate cancer continues to push demand for new therapeutic options. As per the World Cancer Research Fund, 1,467,854 new cancer cases were recorded in 2022, highlighting the increasing need for effective oncological treatments worldwide.

The market's upward trajectory is further fueled by the presence of leading pharmaceutical companies such as Pfizer, Johnson & Johnson, Astellas Pharma, AbbVie, and AstraZeneca, all of which maintain strong pipelines, undertake collaborations, and secure regulatory approvals for innovative mCRPC therapies.

Market Drivers: Innovation and Expanding Treatment Pipelines

One of the principal forces driving market growth is the surge in drug development activities, especially next-generation androgen receptor inhibitors, PARP inhibitors, GnRH agonists, and radiotherapeutics. Companies are increasingly investing in combination therapies aimed at improving survival outcomes in patients who develop ADT resistance.

A notable example is the July partnership between Merck & Co., Inc. and Orion Corporation, focused on developing opevesostat (MK-5684/ODM-208), an investigational CYP11A1 inhibitor for mCRPC. Such advancements highlight the increasing emphasis on targeted, personalized oncology.

Market Restraints: Treatment Resistance and Adverse Effects

Despite promising developments, mCRPC therapeutics face critical challenges. Hormonal therapy resistance remains a major limiting factor in clinical adoption. Cancer cells adapt over time, mutating androgen receptors and reducing treatment effectiveness. Research from the UCLA Jonsson Comprehensive Cancer Center in 2023 highlighted that tumors become less "luminal" over time, reducing responsiveness to hormone therapy and complicating treatment planning.

Additionally, mCRPC drugs-including ZYTIGA, enzalutamide, and abiraterone-are associated with side effects such as hypertension, muscle discomfort, edema, and arrhythmia, which may impede long-term adherence.

Opportunities: Radiotheranostics and Precision Medicine

The emergence of radiotheranostics is creating new opportunities in the mCRPC landscape. These approaches combine diagnostic imaging with targeted radiopharmaceutical therapy, enhancing efficacy and reducing toxicity. In 2023, Clarity Pharmaceuticals advanced its Phase I/IIa SECuRE trial evaluating 64Cu/67Cu-SAR-bisPSMA, reinforcing the shift toward personalized, biomarker-driven mCRPC treatment strategies.

Segmental Insights

Androgen receptor inhibitors dominated the market in 2024 due to their pivotal role in blocking testosterone-driven cancer growth.

On the route-of-administration front, oral drugs held the largest share, driven by patient convenience and the launch of new oral formulations such as relugolix.

Hormonal therapy remained the most widely used treatment class, supported by robust adoption of ADT in early and advanced prostate cancer stages.

Regional Outlook

• North America reached USD 8.85 billion in 2024, benefiting from high diagnosis rates, strong clinical research activity, and early access to new drug launches.
• Europe remains the second-largest market, bolstered by awareness campaigns such as Movember and the release of advanced diagnostic tools.
• Asia Pacific is projected to be the fastest-growing region through 2032, fueled by rising prevalence in China, Japan, Australia, and India, along with increased investments in oncology research.
• Latin America and Middle East & Africa are poised for steady growth due to improving cancer care infrastructure and growing patient access to advanced therapeutics.

Competitive Landscape

Key players include Pfizer Inc., Johnson & Johnson Services, Inc., Astellas Pharma Inc., AbbVie Inc., AstraZeneca, Bayer AG, Tolmar Inc., Dendreon Pharmaceuticals LLC, and others. Major industry developments include FDA approvals for new PARP inhibitor combinations and radioligand therapies such as Pluvicto.

Segmentation By Drug Class

• Androgen Receptor Inhibitors
• Microtubule Inhibitors
• Gonadotropin Releasing Hormone (GnRH) Agonist
• Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
• Others

By Route of Administration

• Oral
• Parenteral

By Therapy

• Chemotherapy
• Hormonal Therapy
• Targeted therapy
• Immunotherapy

By Distribution Channel

• Hospital Pharmacies
• Drug Stores & Retail Pharmacies
• Online Pharmacies

By Geography

• North America (By Drug Class, By Route of Administration, By Therapy, By Distribution Channel, and By Country)
  • U.S.
  • Canada
• Europe (By Drug Class, By Route of Administration, By Therapy, By Distribution Channel, and By Country/Sub-Region)
  • U.K.
  • Germany
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific (By Drug Class, By Route of Administration, By Therapy, By Distribution Channel, and By Country/Sub-Region)
  • Japan
  • China
  • India
  • Australia
  • Rest of Asia Pacific
• Latin America (By Drug Class, By Route of Administration, By Therapy, By Distribution Channel, and By Country/Sub-Region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa ( By Drug Class, By Route of Administration, By Therapy, By Distribution Channel, and By Country/Sub-Region)
  • GCC
  • South Africa
  • Rest of Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Prevalence of Prostate Cancer - by Key Countries/Regions, 2024
• 4.2. Pipeline Analysis, by Key Players
• 4.3. Overview of Alternative Therapies
• 4.4. Key Start-ups in the Market
• 4.5. New Product Launches, by Key Players
• 4.6. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
• 4.7. Impact of COVID-19 on the Market

5. Global Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2019-2032

• 5.1. Market Analysis, Insights and Forecast - By Drug Class
  • 5.1.1. Androgen Receptor Inhibitors
  • 5.1.2. Microtubule Inhibitors
  • 5.1.3. Gonadotropin Releasing Hormone (GnRH) Agonist
  • 5.1.4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
  • 5.1.5. Others
• 5.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 5.2.1. Oral
  • 5.2.2. Parenteral
• 5.3. Market Analysis, Insights and Forecast - By Therapy
  • 5.3.1. Chemotherapy
  • 5.3.2. Hormonal Therapy
  • 5.3.3. Targeted therapy
  • 5.3.4. Immunotherapy
• 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.4.1. Hospital Pharmacies
  • 5.4.2. Drug Stores & Retail Pharmacies
  • 5.4.3. Online Pharmacies
• 5.5. Market Analysis, Insights and Forecast - Region
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia Pacific
  • 5.5.4. Latin America
  • 5.5.5. Middle East & Africa

6. North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2019-2032

• 6.1. Market Analysis, Insights and Forecast - By Drug Class
  • 6.1.1. Androgen Receptor Inhibitors
  • 6.1.2. Microtubule Inhibitors
  • 6.1.3. Gonadotropin Releasing Hormone (GnRH) Agonist
  • 6.1.4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
  • 6.1.5. Others
• 6.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 6.2.1. Oral
  • 6.2.2. Parenteral
• 6.3. Market Analysis, Insights and Forecast - By Therapy
  • 6.3.1. Chemotherapy
  • 6.3.2. Hormonal Therapy
  • 6.3.3. Targeted therapy
  • 6.3.4. Immunotherapy
• 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.4.1. Hospital Pharmacies
  • 6.4.2. Drug Stores & Retail Pharmacies
  • 6.4.3. Online Pharmacies
• 6.5. Market Analysis, Insights and Forecast - By Country
  • 6.5.1. U.S.
  • 6.5.2. Canada

7. Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2019-2032

• 7.1. Market Analysis, Insights and Forecast - By Drug Class
  • 7.1.1. Androgen Receptor Inhibitors
  • 7.1.2. Microtubule Inhibitors
  • 7.1.3. Gonadotropin Releasing Hormone (GnRH) Agonist
  • 7.1.4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
  • 7.1.5. Others
• 7.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 7.2.1. Oral
  • 7.2.2. Parenteral
• 7.3. Market Analysis, Insights and Forecast - By Therapy
  • 7.3.1. Chemotherapy
  • 7.3.2. Hormonal Therapy
  • 7.3.3. Targeted therapy
  • 7.3.4. Immunotherapy
• 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.4.1. Hospital Pharmacies
  • 7.4.2. Drug Stores & Retail Pharmacies
  • 7.4.3. Online Pharmacies
• 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 7.5.1. Germany
  • 7.5.2. U.K.
  • 7.5.3. France
  • 7.5.4. Italy
  • 7.5.5. Spain
  • 7.5.6. Scandinavia
  • 7.5.7. Rest of Europe

8. Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2019-2032

• 8.1. Market Analysis, Insights and Forecast - By Drug Class
  • 8.1.1. Androgen Receptor Inhibitors
  • 8.1.2. Microtubule Inhibitors
  • 8.1.3. Gonadotropin Releasing Hormone (GnRH) Agonist
  • 8.1.4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
  • 8.1.5. Others
• 8.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 8.2.1. Oral
  • 8.2.2. Parenteral
• 8.3. Market Analysis, Insights and Forecast - By Therapy
  • 8.3.1. Chemotherapy
  • 8.3.2. Hormonal Therapy
  • 8.3.3. Targeted therapy
  • 8.3.4. Immunotherapy
• 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.4.1. Hospital Pharmacies
  • 8.4.2. Drug Stores & Retail Pharmacies
  • 8.4.3. Online Pharmacies
• 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 8.5.1. China
  • 8.5.2. Japan
  • 8.5.3. India
  • 8.5.4. Australia
  • 8.5.5. Southeast Asia
  • 8.5.6. Rest of Asia Pacific

9. Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2019-2032

• 9.1. Market Analysis, Insights and Forecast - By Drug Class
  • 9.1.1. Androgen Receptor Inhibitors
  • 9.1.2. Microtubule Inhibitors
  • 9.1.3. Gonadotropin Releasing Hormone (GnRH) Agonist
  • 9.1.4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
  • 9.1.5. Others
• 9.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 9.2.1. Oral
  • 9.2.2. Parenteral
• 9.3. Market Analysis, Insights and Forecast - By Therapy
  • 9.3.1. Chemotherapy
  • 9.3.2. Hormonal Therapy
  • 9.3.3. Targeted therapy
  • 9.3.4. Immunotherapy
• 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.4.1. Hospital Pharmacies
  • 9.4.2. Drug Stores & Retail Pharmacies
  • 9.4.3. Online Pharmacies
• 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 9.5.1. Brazil
  • 9.5.2. Mexico
  • 9.5.3. Rest of Latin America

10. Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2019-2032

• 10.1. Market Analysis, Insights and Forecast - By Drug Class
  • 10.1.1. Androgen Receptor Inhibitors
  • 10.1.2. Microtubule Inhibitors
  • 10.1.3. Gonadotropin Releasing Hormone (GnRH) Agonist
  • 10.1.4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
  • 10.1.5. Others
• 10.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 10.2.1. Oral
  • 10.2.2. Parenteral
• 10.3. Market Analysis, Insights and Forecast - By Therapy
  • 10.3.1. Chemotherapy
  • 10.3.2. Hormonal Therapy
  • 10.3.3. Targeted therapy
  • 10.3.4. Immunotherapy
• 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 10.4.1. Hospital Pharmacies
  • 10.4.2. Drug Stores & Retail Pharmacies
  • 10.4.3. Online Pharmacies
• 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 10.5.1. GCC
  • 10.5.2. South Africa
  • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2024)
• 11.2. Company Profiles
  • 11.2.1. Astellas Pharma Inc.
    • 11.2.1.1. Overview
    • 11.2.1.2. Products
    • 11.2.1.3. SWOT Analysis
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. Financials (Based on Availability)
  • 11.2.2. Pfizer Inc.
    • 11.2.2.1. Overview
    • 11.2.2.2. Products
    • 11.2.2.3. SWOT Analysis
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. Financials (Based on Availability)
  • 11.2.3. Johnson & Johnson Services, Inc.
    • 11.2.3.1. Overview
    • 11.2.3.2. Products
    • 11.2.3.3. SWOT Analysis
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. Financials (Based on Availability)
  • 11.2.4. Sanofi
    • 11.2.4.1. Overview
    • 11.2.4.2. Products
    • 11.2.4.3. SWOT Analysis
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. Financials (Based on Availability)
  • 11.2.5. Ferring Pharmaceuticals Inc.
    • 11.2.5.1. Overview
    • 11.2.5.2. Products
    • 11.2.5.3. SWOT Analysis
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. Financials (Based on Availability)
  • 11.2.6. Sumitomo Pharma Co., Ltd. (Myovant Sciences GmbH)
    • 11.2.6.1. Overview
    • 11.2.6.2. Products
    • 11.2.6.3. SWOT Analysis
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. Financials (Based on Availability)
  • 11.2.7. AbbVie Inc.
    • 11.2.7.1. Overview
    • 11.2.7.2. Products
    • 11.2.7.3. SWOT Analysis
    • 11.2.7.4. Recent Developments
    • 11.2.7.5. Strategies
    • 11.2.7.6. Financials (Based on Availability)
  • 11.2.8. AstraZeneca
    • 11.2.8.1. Overview
    • 11.2.8.2. Products
    • 11.2.8.3. SWOT Analysis
    • 11.2.8.4. Recent Developments
    • 11.2.8.5. Strategies
    • 11.2.8.6. Financials (Based on Availability)
  • 11.2.9. Tolmar, Inc.
    • 11.2.9.1. Overview
    • 11.2.9.2. Products
    • 11.2.9.3. SWOT Analysis
    • 11.2.9.4. Recent Developments
    • 11.2.9.5. Strategies
    • 11.2.9.6. Financials (Based on Availability)
  • 11.2.10. Dendreon Pharmaceuticals LLC.
    • 11.2.10.1. Overview
    • 11.2.10.2. Products
    • 11.2.10.3. SWOT Analysis
    • 11.2.10.4. Recent Developments
    • 11.2.10.5. Strategies
    • 11.2.10.6. Financials (Based on Availability)
  • 11.2.11. Bayer AG
    • 11.2.11.1. Overview
    • 11.2.11.2. Products
    • 11.2.11.3. SWOT Analysis
    • 11.2.11.4. Recent Developments
    • 11.2.11.5. Strategies
    • 11.2.11.6. Financials (Based on Availability)